Last reviewed · How we verify

Sutent — Competitive Intelligence Brief

Sutent (Sunitinib Malate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule kinase inhibitor. Area: Oncology.

marketed Small molecule kinase inhibitor Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sutent (Sunitinib Malate) — Pfizer. Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sutent TARGET Sunitinib Malate Pfizer marketed Small molecule kinase inhibitor Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET 2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule kinase inhibitor class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sutent — Competitive Intelligence Brief. https://druglandscape.com/ci/sutent. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: